Moreover, the systematic approach to TAA prioritization, as demonstrated by Schossig et al., further refines the selection process for potential immunotherapy targets, ensuring that the most promising candidates, like KIF20A, are brought to the forefront of cancer research and treatment. This evidence concerns the gene KIF20A and cancer.